The study of Abrego and colleagues has revealed the part-time function of the metabolic enzyme GOT2 in pancreatic cancer: the GOT2-PPARδ axis significantly regulates the immune microenvironment of pancreatic cancer to inhibit anti-tumor immunity. This evidence concerns the gene PPARD and familial pancreatic carcinoma.